

UGL Limited Group Office

ABN: 85 009 180 287 Level 10, 40 Miller Street North Sydney NSW 2060 Australia

Telephone: +61 2 9492 8888 Facsimile: +61 2 9492 8844

www.ugllimited.com

To: ASX Market Announcements

From: Lyn Nikolopoulos
Pages: 9 (incl. this page)
Date: 15 November 2016

Subject Appendix 3B

Please find attached an Appendix 3B for the grant of rights under UGL's Deferred STI plan for FY2016.

UGL has been granted a waiver from listing rule 7.9 which, subject to satisfaction of a number of conditions, permits UGL to grant these rights. Further details on the waiver and the conditions are set out in section 9.6 of the Target's Statement dated 7 November 2016. Any shares allocated on vesting of the rights within the period of 3 months after UGL was notified of CIMIC Group Investments No.2 Pty Limited's (CIMIC) offer will be satisfied solely by the transfer of existing shares previously acquired on market from the UGL employee share plan trust to the relevant employees. The remaining conditions applying to the waiver have been satisfied, having regard to CIMIC's Fourth Supplementary Bidders' Statement that the offer for shares in UGL Limited is free of the 'prescribed occurrences' condition contained in section 9.8 of the Bidder's Statement.

The proposed treatment of these rights is set out section 9.5(c) of the Target's Statement. In summary, the rights will vest in full, on and with effect from the date CIMIC achieves a shareholding of 50% or more, or a change of control occurs as defined in section 50AA of the Corporations Act.

Your sincerely

Lyn Nikolopoulos

Company Secretary

www.ugllimited.com Page 1 of 1

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity	
UGL I	imited	
ABN		
85 00	9 180 287	
We (the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	th sheets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Rights (unquoted)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	279, 264
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	The rights are granted under UGL's FY16 Deferred STI Plan. Ordinarily the rights vest on 1 September 2018. Please refer to sections 9.5 and 9.6 of UGL's Target's Statement dated 7 November 2016, which outlines the effect of the takeover offer by CIMIC on the rights.
		At vesting, the rights will convert to ordinary

shares on a one for one basis.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No, the rights do not rank equally with the existing class of quoted securities.

The rights do not have any voting rights or rights to receive dividends.

If the rights vest and are converted to ordinary shares, those ordinary shares will rank equally with existing fully paid ordinary shares (including the right to vote and receive dividends).

	T	•		• 1	•
5	Issue	price	or	consid	leration
,			-		

In satisfaction of FY16 deferred short term incentive entitlements.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) The rights are granted under UGL's Deferred STI Plan in relation to FY2016.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

Not applicable

Not applicable

6b The date the security holder resolution under rule 7.1A was passed

6c Number of *securities issued without security holder approval under rule 7.1

Not applicable

6d Number of *securities issued with security holder approval under rule 7.1A

Not applicable

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

ordinary

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	Exercise Price (A\$)	Expiry date /vesting date	Class
279,264	NIL	01/09/2018	Rights
389,155	NIL	01/09/2017	Rights
2,992,378	NIL	01/09/2017	Performance Rights
3,236,752	NIL	01/09/2018	Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The rights do not have rights to receive dividends.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
	B. 11. 10. 11. 17.	Day (A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
		uotation of Securitie	S – Not applicable oplying for quotation of securities
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other ⁺ securities	
			nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addi	tional	securities forming a nev	v class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36			securities, a distribution schedule of the additional umber of holders in the categories
		1,001 - 5,000 5,001 - 10,000	
		10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for	the additional *securities
Entiti	es tha	t have ticked box 34(b) -	Not applicable
38		per of *securities for which action is sought	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

[†] Class of [†] securities for which quotation is sought	
Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	
(if issued upon conversion of another *security, clearly identify that other *security)	
Number +Class	
42 Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	[signed] (Company secretary)	Date: 15 November 2016
Print name:	Lyn Nikolopoulos	

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.